<code id='8D9B9DE746'></code><style id='8D9B9DE746'></style>
    • <acronym id='8D9B9DE746'></acronym>
      <center id='8D9B9DE746'><center id='8D9B9DE746'><tfoot id='8D9B9DE746'></tfoot></center><abbr id='8D9B9DE746'><dir id='8D9B9DE746'><tfoot id='8D9B9DE746'></tfoot><noframes id='8D9B9DE746'>

    • <optgroup id='8D9B9DE746'><strike id='8D9B9DE746'><sup id='8D9B9DE746'></sup></strike><code id='8D9B9DE746'></code></optgroup>
        1. <b id='8D9B9DE746'><label id='8D9B9DE746'><select id='8D9B9DE746'><dt id='8D9B9DE746'><span id='8D9B9DE746'></span></dt></select></label></b><u id='8D9B9DE746'></u>
          <i id='8D9B9DE746'><strike id='8D9B9DE746'><tt id='8D9B9DE746'><pre id='8D9B9DE746'></pre></tt></strike></i>

          knowledge

          knowledge

          author:explore    Page View:6814
          Two researchers look at a computer monitor showing a graph and other data
          Adobe

          Research universities are voicing concerns over some proposed changes to the process for reviewing scientific misconduct allegations, citing worries that new government requirements would hobble their own independent procedures and constitute a huge administrative burden.

          Nearly two decades since it last released research misconduct rules, the U.S. Office of Research Integrity (ORI) is ready to update its requirements for ensuring the scientific standards of projects funded by the U.S. Department of Health and Human Services, including the National Institutes of Health.

          advertisement

          The proposed changes, published on Oct. 6, include a new formal process that institutions would follow in reviewing allegations, a 30-day deadline for institutions to assess allegations, and provisions that make it harder to quickly dismiss cases that institutions believe to be “honest errors.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more
          Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma
          Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

          AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          Merus drug and Keytruda shrank tumors in patients with head and neck cancer

          ThisimmunofluorescenceimageshowsTcells(ingreenandyellow)inthemicroenvironmentofaheadandnecksquamousc